Amphastar Pharmaceuticals... (AMPH)
31.35
0.14 (0.45%)
At close: Feb 20, 2025, 3:59 PM
31.65
0.96%
After-hours: Feb 20, 2025, 04:14 PM EST
undefined% (undefined)
| Bid | 31 |
| Market Cap | 1.51B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 3.01 |
| PE Ratio (ttm) | 10.42 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 34.5 |
| Volume | 455,355 |
| Avg. Volume (20D) | 549,318 |
| Open | 31.20 |
| Previous Close | 31.21 |
| Day's Range | 30.95 - 31.41 |
| 52-Week Range | 30.34 - 56.38 |
| Beta | undefined |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Eno...
Sector Healthcare
IPO Date Jun 25, 2014
Employees 1,761
Stock Exchange NASDAQ
Ticker Symbol AMPH
Website https://www.amphastar.com
Analyst Forecast
According to 4 analyst ratings, the average rating for AMPH stock is "Hold." The 12-month stock price forecast is $55, which is an increase of 75.44% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Amphastar Pharmaceuticals Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-13.69%
Amphastar Pharma shares are trading lower after th...
Unlock content with
Pro Subscription
6 months ago
+13.29%
Amphastar Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
